Minapharm signed deal to produce Sputnik V at its Cairo-based facility
By Staff Writer, Mubasher
Cairo – The Egyptian Exchange (EGX) halted trading on the shares of Minapharm Pharmaceuticals.
Trading will remain suspended on the company’s stock until it responds to news reports about signing an agreement with the Russian Direct Investment Fund (RDIF) to manufacture Sputnik V, the Russian vaccine against coronavirus (COVID-19), at its Cairo-based facility, the EGX said in a statement on Thursday.
Russia’s sovereign wealth fund announced signing an agreement with Minapharm to manufacture more than 40 million doses annually of Sputnik V.
Over the course of 2020, Minapharm achieved net profits of EGP 300.78 million, compared to EGP 141.09 million a year earlier, including minority shareholders’ rights.
The sales increased to EGP 2.36 billion last year from EGP 2.051 billion in 2019.
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
Get Zawya's daily newsletter for insightful and exclusive Middle East perspectives on business and finance. SUBSCRIBE NOW